Tom Powles, MBBS, MRCP, MD

home / authors / tom-powles-mbbs-mrcp-md

Articles

Unmet Needs and the Future of Kidney Cancer

Tom Powles, MBBS, MRCP, MD;Brian Shimkus, MD

June 2nd 2022

Drs Tom Powles and Brian Shimkus muse on the unmet needs of kidney cancers and treatments on the horizon to look forward to.

Treatment Approaches for Good Risk Patients with Renal Cell Carcinoma

Tom Powles, MBBS, MRCP, MD;Brian Shimkus, MD

June 2nd 2022

A discussion on how patient risk groups play into deciding on the appropriate treatment for renal cell carcinoma.

Choosing a Combination Therapy for Renal Cell Carcinoma Before and After CLEAR Data

Brian Shimkus, MD;Tom Powles, MBBS, MRCP, MD

May 26th 2022

Brian Shimkus, MD, discusses how he chose between RCC combination therapies before CLEAR trial data, and how the data influences his decisions now.

Dose Reductions and Treatment Breaks on Lenvatinib Therapy

Tom Powles, MBBS, MRCP, MD;Brian Shimkus, MD

May 26th 2022

Dr Brian Shimkus describes how he doses lenvatinib for renal cell carcinoma treatment.

Choosing Therapies for Patients with Advanced Renal Cell Carcinoma

Tom Powles, MBBS, MRCP, MD;Brian Shimkus, MD

May 19th 2022

A physician explains why he doesn’t believe there is a “typical” patient and why advanced RCC therapies must be tailored to each case.

Conclusions: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Brian I. Rini, MD;Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

May 2nd 2022

Brian Rini, MD, summarizes the thoughts of his colleagues on the use of lenvatinib plus pembrolizumab to treat advanced renal cell carcinoma.

The Exciting Future of Advanced Renal Cell Carcinoma Management

Marie Carlo, MD;Mehmet Asim Bilen, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

May 2nd 2022

A panel of oncologists look at what’s in the pipeline for advanced renal cell carcinoma, including trials and treatment options.

Unmet Needs in Advanced Renal Cell Carcinoma Management

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

May 2nd 2022

Two kidney cancer experts explore the current unmet needs for patients with advanced renal cell carcinoma.

Unmet Needs in the Front-Line Setting for Renal Cell Carcinoma

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

April 21st 2022

A look at the current unmet needs in front-line renal cell carcinoma treatment.

Patient Quality of Life on Lenvatinib plus Pembrolizumab Treatment for Renal Cell Carcinoma

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

April 21st 2022

Oncologists review quality of life data for patients with renal cell carcinoma receiving lenvatinib plus pembrolizumab combination treatments.

Treating Favorable Risk Patients with Renal Cell Carcinoma with Lenvatinib

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

April 19th 2022

Experts discuss the safety of treating renal cell carcinoma with lenvatinib within different patient risk populations.

Risk Factors in the Management of Advanced Renal Cell Carcinoma

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

April 19th 2022

Possible comorbidities and other risk factors in advanced renal cell carcinoma that would affect potential treatment regimens.

Choosing a Combination Treatment for Advanced Renal Cell Carcinoma

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

April 4th 2022

A look at the factors considered in choosing an appropriate combination treatment for advanced renal cell carcinoma.

Choosing a First-Line Combination Treatment Regimen for Renal Cell Carcinoma

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

April 4th 2022

Drs Rana McKay and Tom Powles debate the merits of different first-line combination treatment regimens for renal cell carcinoma.

A Physician’s Take on the CLEAR Trial Data

Brian Shimkus, MD;Tom Powles, MBBS, MRCP, MD

March 31st 2022

Brian Shimkus, MD, shares his opinion of data on lenvatinib and pembrolizumab from the CLEAR trial.

Incorporating Data from the CLEAR Trial into Clinical Practice

Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

March 25th 2022

Experts discuss how data from the CLEAR trial affects the management of advanced renal cell carcinoma in their clinical practices.

Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma: Key Takeaways

Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

March 25th 2022

Rana McKay, MD, and Tom Powles, MBBS, MRCP, MD, highlight key data from the CLEAR trial and offer their overall opinions on the combination of lenvatinib plus pembrolizumab for the treatment of renal cell carcinoma [RCC].

Impressions of Data and Results from the CLEAR Trial

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

March 18th 2022

Oncologists give their initial impressions about the results of a clinical trial studying doublet combination therapies for advanced renal cell carcinoma.

Background: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

March 18th 2022

Robert J. Motzer, MD, presents data examined in the article, “Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.”